Verbatim response from ChatGPT
Short answer: probably not. Compounded “GLP‑1 drops” or home‑made tablets generally aren’t proven to work the way prescription GLP‑1 drugs do, and they carry safety and quality risks. If you want an oral GLP‑1 that’s been shown to work, the only FDA‑approved option is oral semaglutide (Rybelsus). Otherwise, the evidence and regulatory oversight are with the approved injectable drugs.
What’s going on (brief):
- GLP‑1 drugs are peptides. Taken by mouth they’re usually destroyed in the gut and/or are poorly absorbed unless specially formulated. Pharmaceutical companies use specific chemistry and absorption enhancers (for example, Rybelsus contains the SNAC absorption enhancer) and test stability, dosing, and safety in clinical trials.
- Compounding pharmacies sometimes make sublingual “drops” or custom tablets and advertise that these bypass the gut. There are no credible, peer‑reviewed clinical trials showing these compounded products are bioequivalent, safe, or effective compared with approved medicines. Peptides are hard to formulate for reliable mucosal absorption; potency, purity and dose consistency in compounded products can vary.
- Compounded products are not held to the same manufacturing and regulatory standards as FDA‑approved drugs. That raises risks for contamination, wrong dose, degraded drug, or fraud.
What the evidence/regulatory landscape says:
- Rybelsus (oral semaglutide) is the only FDA‑approved oral GLP‑1; it has documented efficacy and specific dosing instructions to maximize absorption (take on empty stomach with a small amount of water, wait 30–60 minutes before eating/other meds).
- Most other GLP‑1s (semaglutide as Ozempic/Wegovy, tirzepatide as Mounjaro/Zepbound, liraglutide/Victoza/Saxenda, dulaglutide/Trulicity, exenatide/Byetta) are injectables with large, high‑quality trial evidence for blood sugar control and/or weight loss.
- There are ongoing research efforts for alternative oral or inhaled peptide delivery methods, but until those formulations are approved and studied, compounded versions remain unproven.
Safety and legal notes:
- Using compounded GLP‑1s risks getting under‑dosed (no effect) or contaminated/dangerous product.
- Compounding pharmacies can legally make individualized meds, but they cannot lawfully sell copies of commercially available FDA‑approved drugs as routine substitutes.
- If you encounter a compounded product that caused harm or seems fraudulent, report it to FDA MedWatch.
Practical recommendation:
- If you want an oral medication: talk to your clinician about Rybelsus (oral semaglutide). It’s the proven, approved oral option.
- If you want the strongest, best‑studied weight‑loss or glucose‑lowering effect, discuss injectable options with your doctor (Ozempic/Wegovy for semaglutide; Mounjaro or Zepbound for tirzepatide — your prescriber can advise which fits your situation).
- Avoid unproven compounded drops/tablets. If a compounding route is being considered for a specific medical need, insist on a reputable, licensed compounding pharmacy (USP compliance, state licensure) and discuss risks with your prescriber.
Brands to discuss with your clinician:
- Rybelsus (oral semaglutide) — only approved oral GLP‑1; shown effective when taken exactly as directed.
- Ozempic (semaglutide) — proven for type 2 diabetes (injectable).
- Wegovy (semaglutide) — approved for chronic weight management (injectable).
- Mounjaro (tirzepatide) — powerful injectable for type 2 diabetes; tirzepatide formulations for weight (Zepbound) exist for obesity treatment.
- Trulicity (dulaglutide), Victoza (liraglutide), Saxenda (liraglutide for weight) — other approved GLP‑1 injectables.
If you want, tell me why you’re considering oral compounded GLP‑1 (cost, needle phobia, access, etc.), and I can suggest safer, practical alternatives, including how to talk to your prescriber about Rybelsus or injection options and how to find assistance programs or specialist care.